Drug Profile
Research programme: YSCMA monoclonal antibodies - Y's Therapeutics
Alternative Names: AntCyc; YSCMA programme; YSCMA-1L; YSCMA-3L; YSCMA-ATL; YSCMA-GVLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ys Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in Japan (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Japan (Parenteral)
- 04 Nov 2009 Preclinical development is ongoing in Japan